Our mission.

We are revolutionising protein diagnostics. As leading researchers in the field of protein science, our goal is to detect neurodegenerative diseases at an early stage in order to prevent their symptomatic progression.

Groundbreaking analysis.

betaSENSE technology detects changes in relevant proteins in the body long before the first symptoms of neurodegenerative diseases appear. Thanks to this technology, it is possible to accurately determine an individual’s risk of disease based on analyses of bodily fluids. This should give doctors and patients a valuable head start in terms of treatment options – while also paving the way for the development of new drugs. So that self-determination in old age becomes a matter of course in the future.

The management

Prof. Dr. Klaus Gerwert

Founder & CEO

Learn more

As a leading researcher at Ruhr University Bochum, Prof. Dr. Klaus Gerwert initiated the spin-off of his protein diagnostics project – marking the birth of betaSENSE.

The betaSENSE teams – a wealth of expertise, one common goal.

At betaSENSE, more than 30 employees are currently working to combat neurodegenerative diseases such as Alzheimer’s and Parkinson’s at an early stage. Combining the collective strength of various scientific disciplines to advance medical progress.

Clinical trial management & product management

Our team offers professional services for clinical trials with the utmost scientific rigour and regulatory precision. We work closely with trial centres, authorities and partners to ensure safety, quality and efficiency.

At the same time, we are strategically developing our products further based on clinical data, market needs and innovation potential. Through integrated product management, we translate scientific findings into marketable solutions for patients and partners in a targeted manner.

Research & Development

The Research & Development (R&D) team develops new technologies for applications and products in the field of in vitro diagnostics (IVD). Our expertise is in demand wherever the analysis of bodily fluids is used to draw conclusions about a person's state of health. The team delivers innovative solutions for complex issues, processes and systems.

Software development

The software development team works hand in hand with the R&D team to develop customised and future-proof software solutions for in vitro diagnostics (IVD) applications – from prototype development to the finished solution.

Antibody Development & Production

The antibody team develops disease-specific antibodies and antibody fragments to determine the risk of various neurodegenerative diseases using the betaSENSE method. The team is also responsible for discovering new antibodies against misfolded proteins whose structural changes indicate the onset of disease.

Biochip production

The Biochip team is responsible for producing the sensor, whose patented surface, as part of betaSENSE technology, enables the analysis of various proteins. With its platform technology, it opens up new possibilities for related fields such as pharmaceutical research and science.

Quality management

The Quality Management (QM) team has implemented a reliable QM system at betaSENSE and ensures maximum safety and quality for betaSENSE products and systems on a daily basis. In collaboration with other teams, it ensures a continuous improvement process.

We are working together to ensure that self-determination in old age becomes a matter of course.

Join us!

The betaSENSE
Story.

betaSENSE emerged from a group of researchers at Ruhr University Bochum led by Prof. Dr. Klaus Gerwert. The most important milestones on his journey from basic research to becoming an international pioneer in protein diagnostics since his appointment as professor in 1993:

2014

The Centre for Molecular Protein Diagnostics (PRODI) is approved by the Science Council at Ruhr University Bochum as a scientific project of outstanding importance. Prof. Dr. Klaus Gerwert becomes its founding director. Since then, PRODI has been combining established platform technologies with new methods of protein analysis.

2018

A newly developed blood-based biomarker is gaining international attention. EMBO Journal dedicates its cover story to the infrared sensor for label-free determination of the structure of the beta-amyloid protein.

2020

betaSENSE GmbH was founded in mid-2020 by Prof. Dr. Klaus Gerwert as iR Diagnostic IP holding, a spin-off from Ruhr University Bochum. Later, the UG was converted into betaSENSE GmbH with the entry of Podesta GmbH, a company of the Hector Group. This paves the way for developing a marketable product from a revolutionary technology. The spin-off marks the beginning of a new era in early diagnosis for neurodegenerative diseases.

2021

A team of over 25 employees is working together to bring betaSENSE technology to market maturity. The new company headquarters in Bochum, close to Ruhr University Bochum and the Health Campus, offers optimal working conditions in terms of equipment and infrastructure.

2023

Important milestone – CE certification
The measurement prototypes developed pass testing by an external body and obtain the important CE mark.

2024

Prof. Dr. Klaus Gerwert presents the misfolding of alpha-synuclein as a biomarker in body fluids for Parkinson's disease. At an invited lecture at the renowned "International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders", AD/PD for short, in Lisbon, the technology gains further recognition and leaves a lasting impression on the participants.

since 2025

The technology is being used for the first time in a clinical trial to monitor the efficacy of a novel therapy for Parkinson's disease. This represents the first application in the important field of pharmaceutical research.